- Home
- HCM vs SRRK Comparison
HCM vs SRRK Comparison
Compare HCM & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCM
- SRRK
- Stock Information
- Founded
- HCM 2000
- SRRK 2012
- Country
- HCM Hong Kong
- SRRK United States
- Employees
- HCM N/A
- SRRK N/A
- Industry
- HCM Biotechnology: Pharmaceutical Preparations
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HCM Health Care
- SRRK Health Care
- Exchange
- HCM Nasdaq
- SRRK Nasdaq
- Market Cap
- HCM 2.8B
- SRRK 3.2B
- IPO Year
- HCM N/A
- SRRK 2018
- Fundamental
- Price
- HCM $15.93
- SRRK $32.22
- Analyst Decision
- HCM
- SRRK Strong Buy
- Analyst Count
- HCM 0
- SRRK 8
- Target Price
- HCM N/A
- SRRK $44.29
- AVG Volume (30 Days)
- HCM 59.1K
- SRRK 1.8M
- Earning Date
- HCM 08-07-2025
- SRRK 08-06-2025
- Dividend Yield
- HCM N/A
- SRRK N/A
- EPS Growth
- HCM N/A
- SRRK N/A
- EPS
- HCM 0.53
- SRRK N/A
- Revenue
- HCM $602,197,000.00
- SRRK N/A
- Revenue This Year
- HCM $2.73
- SRRK N/A
- Revenue Next Year
- HCM $17.33
- SRRK $3,116.02
- P/E Ratio
- HCM $5.63
- SRRK N/A
- Revenue Growth
- HCM N/A
- SRRK N/A
- 52 Week Low
- HCM $11.51
- SRRK $6.76
- 52 Week High
- HCM $21.50
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- HCM 50.35
- SRRK 45.00
- Support Level
- HCM $14.69
- SRRK $31.72
- Resistance Level
- HCM $15.50
- SRRK $34.66
- Average True Range (ATR)
- HCM 0.29
- SRRK 2.04
- MACD
- HCM -0.02
- SRRK 0.08
- Stochastic Oscillator
- HCM 65.96
- SRRK 47.23
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.